Which drugs go off patent in 2037?
Two blockbuster drugs with $18.6B in 2025 worldwide sales lose US exclusivity in 2037, led by Trikafta (Vertex, $10.3B). Both are small-molecule drugs that go generic.
| Drug | Company | Area | 2025 sales | Date basis | US copies | Medicare price |
|---|---|---|---|---|---|---|
| Trikafta | Vertex | Other | $10.3B | Patent-expiry estimate | No US filing found | – |
| Rinvoq | AbbVie | Immunology | $8.3B | Settlement / court date | Filed with the FDA | – |
One of these dates is fixed by a launch, settlement, court ruling or company guidance; one is an estimate from patent expiry and could move. Each drug's page has the sources.
For shared drugs, each company is credited with the revenue it reports, so nothing is counted twice. Share is of the company's total 2025 revenue.
Generic launches usually take most of a drug's US volume within months.
US exclusivity can end earlier or later than these dates if a court ruling, settlement or new patent changes the picture. See what happened to sales after past patent cliffs →